ArticleRNA biology2026
LINC00852 inhibits colorectal cancer progression by regulating cell apoptosis, epithelial‒mesenchymal transition, invasion, and cuproptosis through miR-1276/LACTB.
Article in RNA biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exploring the role of key genes in colorectal cancer (CRC) progression to identify effective targets is highly practical. Previous studies have shown that miR-1276/ACTB plays an important regulatory role in CRC. In addition to miRNA, lncRNA also play a crucial role in tumour progression. However, there are currently no studies exploring the relationship between lncRNAs and miR-1276/LACTB. Analysis of the relationship between lncRNAs and miR-1276 using ENCORI database showed that lncRNA-LINC00852 bound to miR-1276 and inhibited its expression, thereby promoting LACTB expression, and miR-1276 upregulation weakened the ability of LINC00852 to promote LACTB expression. ENCORI and TCGA data also indicated that the expression of LINC00852 and LACTB in CRC was significantly downregulated, while miR-1276 expression was significantly upregulated. LINC00852 overexpression promoted E-cadherin expression, increased the activities of Caspase-3/8/9 and PARP, inhibited the expression of N-cadherin and Vimentin, and decreased the expression and secretion of MMP-2 and MMP-9. LINC00852 inhibited CRC cell viability, invasion and migration while promoting apoptosis. miR-1276 overexpression or LACTB knockdown significantly blocked the regulatory effect of LINC00852 on CRC cell biological function. Further xenograft mouse model confirmed that LINC00852 downregulated miR-1276 expression, enhanced the expression of LACTB and FDX1, increased tumour copper levels and inhibited tumour formation, indicating that the anticancer effect of LINC00852/LACTB may also be related to cuproptosis. However, LACTB knockdown blocked the inhibitory effect of LINC00852 on tumour formation. Therefore, LINC00852 inhibits CRC progression through miR-1276/LACTB, indicating that LINC00852/miR-1276/LACTB axis is an important pathway closely related to the occurrence and development of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.